加载中
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
收盘时
US$7.46
+US$0.08 · +1.08%
盘后
US$7.46
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日内区间
当前US$7.46
52周区间
当前US$7.46
盘中时间采用ET。市场数据可能有所延迟。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日内区间
当前US$7.46
52周区间
当前US$7.46
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.12亿 USD | 4347.22万 USD | — | 6.54万 USD | 19.09万 USD |
| 销货成本 | 3596.1万 USD | 319.05万 USD | 20.56万 USD | 3734 USD | 14.89万 USD |
| 毛利 | 2.76亿 USD | 4028.16万 USD | −20.56万 USD | 6.17万 USD | 4.2万 USD |
| 研究与开发 | 1933.3万 USD | 394.23万 USD | 1315.51万 USD | 1067.95万 USD | 1313.3万 USD |
| 销售、一般及管理费用 | 3016.6万 USD | 5869.58万 USD | 3580.27万 USD | 2000.61万 USD | 1634.66万 USD |
| 营业费用 | 1.26亿 USD | 6263.8万 USD | 4875.22万 USD | 3068.56万 USD | 2947.96万 USD |
| 利息收入 | 384.6万 USD | 257.88万 USD | 268.19万 USD | 32.6万 USD | 1.44万 USD |
| 利息支出 | 278.2万 USD | 3.64万 USD | 3.43万 USD | 2.65万 USD | 1.59万 USD |
| 折旧和摊销 | 1454.9万 USD | 31万 USD | 7.08万 USD | 8.46万 USD | 6.19万 USD |
| 营业利润 | 1.5亿 USD | −2235.64万 USD | −4895.78万 USD | −3062.4万 USD | −2943.76万 USD |
| 净利润 | 1.63亿 USD | −1793万 USD | −4633.92万 USD | −2970.17万 USD | −2821.02万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$14.50
上涨空间 94.37%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年3月26日 | 1:5 | — | — |
已生效 2019年3月26日
1:5
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1840.1万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Avantis U.S. Small Cap Value ETFAVUV1674.31万0.05%308.51亿 USD0.25%US$119.94+0.25%
iShares Russell 2000 ETFIWM1450.53万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF697.56万0.01%954亿 USD0.05%US$233.52-0.63%
State Street SPDR S&P Pharmaceuticals ETFXPH558.86万1.21%4.62亿 USD0.35%US$64.01-0.99%
Pacer US Small Cap Cash Cows ETFCALF489.28万0.14%35.87亿 USD0.59%US$54.76+0.18%
Vanguard Russell 2000 ETFVTWO353.95万0.02%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA254.56万0.01%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIAvantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
